ERG and prostate cancer: In a meta-analysis by Itkonen and colleagues, GUCY1A1 was identified as an AR- and ERG-upregulated target involved in the hexosamine biosynthesis pathway (HBP), which is overexpressed in clinical cases of prostate cancer [153].